IRB Number
|
# 26942
|
| Description |
This research study will evaluate
the efficacy and safety of repeat oral doses of a study medication in
subjects with a low platelet count with Hepatitis C. |
| What is expected of me? |
Open-label oral dose escalation
for up to 9 weeks before being randomized to double-blind study medication
or placebo in combination with antiviral therapy for up to 48 weeks. |
| Inclusion Criteria |
Men and women ≥ 18 yrs. old, chronic Hepatitis C infection, appropriate
candidates for Peginterferon alfa-2a and Ribavirin combination, platelet
count <75,000. |
| Exclusion Criteria |
Non-responders to previous treatment with peginterferon and Ribavirin for
reasons other than low platelet count. |
| Length of Study |
Approximately 2 years |
| Study Location |
Penn State Milton S. Hershey
Medical Center |
| Investigator Information |
Thomas R Riley, MD
Gastroenterology & Hepatology |
| To obtain more information about this study please contact: |
Laurie Peiffer
717-531-8259 |
